7 May 2024 • 16:30-18:00 • Multifunctional room E • Session translated simultaneously PL/EN
Industry and manufacturing for the health system. Drug safety on the agenda of the Polish Presidency of the EU Council. Investment – the key role of innovation, the potential of the Polish R&D and biotechnological sector. Foreign expansion of Polish health sector companies. Production and services for health as an element of safety and a source of benefit for the economy and for patients. Research and development centres and hubs, knowledge transfer and new technologies – the non-manufacturing contribution of the health industry to Poland’s GDP.
Director for external relations, ESG and health economics at ADAMED Pharma SA, Deputy President of the Management Board, the Polish Association of Employers of the Pharmaceutical Industry – Domestic Pharmaceutical Manufacturers
President of the Management Board, AstraZeneca Pharma Poland
Director of External Relations, Member of the Management Board, GSK Commercial Ltd.
President of the Board, Polish Association of Employers of the Pharmaceutical Industry - National Pharmaceutical Manufacturers, Vice President, Lewiatan Confederation, Member of the Board, Mediciens for Europe
Undersecretary of State, Ministry of Health
Deputy President for Research Financing, Medical Research Agency
You watching archival version of European Economic Congress
What you can do:
Go to the current edition page or Continue browsing